BeyondSpring Inc. (BYSI)
NASDAQ: BYSI · Real-Time Price · USD
1.450
-0.040 (-2.68%)
At close: Mar 6, 2026, 4:00 PM EST
1.360
-0.090 (-6.21%)
After-hours: Mar 6, 2026, 5:08 PM EST
BeyondSpring Employees
BeyondSpring had 40 employees as of December 31, 2024. The number of employees increased by 4 or 11.11% compared to the previous year.
Employees
40
Change (1Y)
4
Growth (1Y)
11.11%
Revenue / Employee
n/a
Profits / Employee
-$14,950
Market Cap
59.63M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 124 |
| InflaRx | 74 |
| Mereo BioPharma Group | 36 |
| eXoZymes | 31 |
| Entera Bio | 22 |
| NeurAxis | 21 |
| Instil Bio | 14 |
| Alterity Therapeutics | 9 |
BYSI News
- 26 days ago - BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference - GlobeNewsWire
- 3 months ago - BeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration Path - GlobeNewsWire
- 6 months ago - BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript) - Seeking Alpha
- 8 months ago - BeyondSpring Publishes Human Clinical Study in Med (Cell Press) Showing Plinabulin-Driven Dendritic Cell Maturation and Tumor Response After Prior Checkpoint Inhibitor Failure - GlobeNewsWire
- 9 months ago - BeyondSpring Presents Efficacy/Safety Data from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at 2025 ASCO Annual Meeting - GlobeNewsWire
- 10 months ago - BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - BeyondSpring Files 2024 Annual Report on Form 10-K - GlobeNewsWire
- 1 year ago - BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies - GlobeNewsWire